Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug;70(4):339-48.
doi: 10.1016/j.neures.2011.05.008. Epub 2011 May 20.

Protein aggregate spreading in neurodegenerative diseases: problems and perspectives

Affiliations
Review

Protein aggregate spreading in neurodegenerative diseases: problems and perspectives

Seung-Jae Lee et al. Neurosci Res. 2011 Aug.

Abstract

Progressive accumulation of specific protein aggregates is a defining feature of many major neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, fronto-temporal dementia, Huntington's disease, and Creutzfeldt-Jakob disease (CJD). Findings from several recent studies have suggested that aggregation-prone proteins, such as tau, α-synuclein, polyglutamine-containing proteins, and amyloid-β, can spread to other cells and brain regions, a phenomenon considered unique to prion disorders, such as CJD and bovine spongiform encephalopathy. Cell-to-cell propagation of protein aggregates may be the general underlying principle for progressive deterioration of neurodegenerative diseases. This may also have significant implications in cell replacement therapies, as evidenced by the propagation of α-synuclein aggregates from host to grafted cells in long-term transplants in Parkinson's patients. Here, we review recent progress in protein aggregate propagation in experimental model systems and discuss outstanding questions and future perspectives. Understanding the mechanisms of this pathological spreading may open the way to unique opportunities for development of diagnostic techniques and novel therapies for protein misfolding-associated neurodegenerative diseases.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Amyloidogenic protein aggregation process. Graph shows kinetics of amyloidogenesis. Black trace represents the general “uninduced” amyloidogenesis, while red trace represents the amyloidogenesis upon “seeding” with preformed aggregates. Process of amyloidogenesis involves several intermediate species, including dimmers, small oligomers, and protofibrils, some of which may have stability and conformational properties for serving as “nucleus” (scheme underneath the black trace). When preformed amyloids are present, these intermediate steps, hence the nucleation steps, are bypassed; monomers are directly recruited to amyloids (scheme above the red trace). Globular oligomers refer to broardly defined oligomeric aggregates, which may include both unstable “pre-nuclear” intermediates and relatively stable intermediates with the characteristics of nucleus. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)
Fig. 2
Fig. 2
Potential mechanisms of protein aggregation induced by aggregates originated from neighboring neurons. The model depicts how protein aggregates originated from one neuron (neuron 1) might induce protein aggregation in another neuron (neuron 2).

References

    1. Aguzzi A, Baumann F, Bremer J. The prion’s elusive reason for being. Annu Rev Neurosci. 2008;31:439–477. - PubMed
    1. Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, Cooper JM. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 2011 - PMC - PubMed
    1. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805–810. - PubMed
    1. Bahr BA, Bendiske J. The neuropathogenic contributions of lysosomal dysfunction. J Neurochem. 2002;83:481–489. - PubMed
    1. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science. 2008;319:916–919. - PubMed

Publication types

MeSH terms

Substances